Stockreport

Eli Lilly Proves Its GLP-1 Dominance Again, Raising My Price Target [Seeking Alpha]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF LLY's 2026 guidance calls for $80–83B revenue and $33.50–35 non-GAAP EPS, outpacing consensus and supporting a reiterated buy rating. Mounjaro and Zepbound drove $6.3 [Read more]